Therefore, these data support our hypothesis that retatrutide, an agonist at recombinant GLP1-R in cell culture, acts in part via GLP1-R in HAP
Tirzepatide produces average weight loss of approximately 20% to 22.5% at its highest approved dose of 15 mg over 72 weeks
Furthermore, patients with established cardiovascular risk may benefit from the cardioprotective effects
Food Choices to Increase GLP-1 The nutrients that help stimulate GLP-1 secretion are typically found in healthy foods included in dietary guidelines
Additionally, our clinicians will monitor your progress and help you manage any potential side effects, such as nausea, vomiting, diarrhea, or constipation, that can occur particularly when beginning treatment or adjusting dosages
As of April 2026, retatrutide is investigational